Phytochemicals targeting Toll-like receptors 4 (TLR4) in inflammatory bowel disease

Chin Med. 2022 Apr 28;17(1):53. doi: 10.1186/s13020-022-00611-w.

Abstract

Inflammatory bowel disease (IBD) is a collective term for inflammatory diseases including Crohn's disease and ulcerative colitis. Toll-like receptor 4 (TLR4) is thought to play a key role in the pathogenesis of IBD. Inhibition of TLR4 has been recognized as an effective target for the treatment of IBD. Many phytochemicals have been shown to have potential as new drugs for the treatment of IBD. This review surveyed the available literature and reports which focused on the in vivo effects of phytochemicals targeting TLR4 in different models of IBD, and clarified the significance of TLR4 as a current therapeutic target for IBD. Based on our review, we have concluded that phytochemicals targeting TLR4 are potentially effective candidates for developing new therapeutic drugs against IBD.

Keywords: Inflammatory bowel disease (IBD); Phytochemicals; Toll-like receptor 4 (TLR4).

Publication types

  • Review